An Investigator-Initiated Open-Label, Randomized Study of Gemcabene in Adults With Familial Partial Lipodystrophy Disease (FPLD)

Trial Profile

An Investigator-Initiated Open-Label, Randomized Study of Gemcabene in Adults With Familial Partial Lipodystrophy Disease (FPLD)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 May 2018

At a glance

  • Drugs Gemcabene (Primary)
  • Indications Lipodystrophy; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms AZURE-1
  • Most Recent Events

    • 21 Dec 2017 According to a Gemphire Therapeutics media release, Elif Oral, MD, Associate Professor of Medicine, Department of Internal Medicine, University of Michigan Medical Center, is the primary investigator of this trial.
    • 21 Dec 2017 According to a Gemphire media release, status changed from planning to recruiting.
    • 25 Sep 2017 According to a Gemphire Therapeutics media release, plans to initiate this trial in the fourth quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top